Bcl-2 promotes oncogenesis by inhibiting cell death. Bcl-2 also inhibits proliferation and suppresses tumorigenesis in some settings. To clarify the role of the antiproliferative function of Bcl-2, mice expressing a mutant form of Bcl-2 reported to lack antiproliferative activity were generated (tyrosine 28 to alanine, Bcl-2-Y28A). As expected, both wild type (WT) and Bcl-2-Y28A inhibited apoptosis similarly. In contrast to previous results in cell lines, Bcl-2-Y28A inhibited T-cell proliferation identical to WTBcl-2. Significantly, both Bcl-2-Y28A and WT-Bcl-2 inhibited proliferation of T cells isolated from older animals, but not proliferation of T cells from immature mice. Instead, inhibition of cell activation correlated with T-cell size, p27 levels, and RNA content, all indicators of quiescent G0 arrest. Consistent with this model, Bcl-2 inhibition of T-cell proliferation was reversed by expression of Bax, again correlating cell proliferation with cell size. These experiments do not support genetically separate effects of Bcl-2 on apoptosis and proliferation. Instead, the data support a model in which Bcl-2 and Bax regulate T-cell proliferation by changes in T-cell size and by increasing the markers of quiescent G0 arrest. These changes likely result from prolonged T-cell survival.
Introduction
Bcl-2 is an oncogene commonly associated with follicular B-cell lymphoma (Tsujimoto et al., 1985) . Bcl-2 is a member of a large family of proteins that are critical regulators of cell death. This family contains both antiapoptotic (such as Bcl-2, Bcl-x) and proapoptotic members (such as Bax, Bak) (Chao and Korsmeyer, 1998; Gross et al., 1999) . Bcl-2 is predominantly a mitochondria protein, and it is able to block a number of mitochondria changes that occur with apoptosis, including loss of mitochondria membrane potential, release of mitochondria proteins cytochrome c and apoptosis-inducing factor (AIF), and opening of the mitochondria permeability transition pore (PTP) (Gross et al., 1999) . The mechanism by which Bcl-2 prevents the release of mitochondria components remains controversial, but Bcl-2 appears to prevent the formation or opening of a large mitochondria channel that involves proapoptotic family members and/or the voltage-dependent anion channel (VDAC) .
Numerous studies in both humans and mice illustrate that Bcl-2 is associated with tumor development (MacCarthy-Morrogh et al., 1999) . However, Bcl-2 expression is not always correlated with accelerated oncogenesis and a poor outcome. Studies of human colon cancer (Ofner et al., 1995; Manne et al., 1997; Kaklamanis et al., 1998; Buglioni et al., 1999; Meterissian et al., 2001 ) and breast cancer (Silvestrini et al., 1994) demonstrated that increased Bcl-2 expression is associated with improved survival. In mice, Bcl-2 expression results in delayed tumor development including hepatocellular carcinoma (de la Coste et al., 1999) , dimethylbenz(a)anthracene-induced mammary tumors (Murphy et al., 1999) , and UV-or chemical-induced epidermal tumors (Rossiter et al., 2001) . In each of these cases, the anti-oncogenic activity of Bcl-2 was correlated with decreased proliferation. Paradoxical effects on oncogenesis by other Bcl-2 family members have also been observed (Bairey et al., 1999; Hogarth and Hall, 1999; Knudson et al., 2001) .
A number of studies have examined the effects of Bcl-2 on cellular proliferation (Vaux et al., 1988; Hockenbery et al., 1990; Marvel et al., 1994) . BAF3 cells expressing Bcl-2 were found to be refractory to readdition of IL-3 (Marvel et al., 1994) . The delay in cell cycle entry, increased with prolonged growth factor deprivation, suggesting Bcl-2 prolongs the G0 to G1 transition. Consistent with this interpretation, there are several reports on the effect of Bcl-2 on resting lymphocytes. In vivo, B cells expressing Bcl-2 show delayed activation following immunization (Strasser et al., 1991) . In vitro, B-lymphocytes from Bcl-2 transgenic mice are remarkably resistant to activation and subsequent proliferation (O'Reilly et al., 1996 (O'Reilly et al., , 1997a . Similarly, activation of T cells from Bcl-2-deficient, heterozygous, wild-type, and transgenic mice showed an inverse correlation between Bcl-2 levels and IL-2 production or cell proliferation (Linette et al., 1996) . This study suggested that the effect of Bcl-2 on proliferation is not limited to cells that have nonphysiological levels of Bcl-2, as the loss of function of Bcl-2 by targeted deletion of the gene accelerated cell division in a dose-dependent manner. Reduced proliferation of lymphocytes was independent of the activating signal, as inhibition is observed following activation with CD3, CD3 þ CD28, concanavalin A þ IL-2, or CD40 þ IL-2. These findings in lymphocytes have been extended to other cell types including NIH 3T3 fibroblast, and IL-3-dependent hematopoietic cell lines (O'Reilly et al., 1996; Huang et al., 1997; Greider et al., 2002) .
A critical question is: Do the same or distinct functions of Bcl-2 account for the antiapoptotic and antiproliferative activities? Substitutions of the conserved tyrosine at position 28 in the BH4 domain of Bcl-2 to alanine, serine, or phenylalanine did not affect the ability of Bcl-2 to inhibit apoptosis. However, FDC-P1 or NIH/3T3 cells expressing mutated Bcl-2 (Y28 A, S or F) failed to inhibit proliferation (Huang et al., 1997) . These authors concluded that Bcl-2 is a multifunctional protein that independently regulates cell cycle and cell death (Huang et al., 1997) . However, these observations have not yet been extended beyond cell lines to animal models or to the proliferation of normal lymphocytes. In this report, we generate transgenic mice expressing Bcl-2-Y28A to determine if these important biological functions of Bcl-2 can be separated in an animal model. Surprisingly, we find that Bcl-2-Y28A inhibits cell proliferation to the same extent as wild-type Bcl-2. Cell cycle inhibition was shown to correlate with age, cell size, and RNA content. We propose that Bcl-2 inhibits T-cell proliferation by prolonging in vivo survival, resulting in changes in cell size and RNA content.
Results

Expression and antiapoptotic function of Lck-Bcl-2-Y28A mice
To determine the role of Y28A mutant Bcl-2 in vivo, transgenic mice expressing Bcl-2-Y28A were generated using the Lck proximal promoter. Thymocytes from five transgenic lines were initially screened for Bcl-2 protein expression in thymocytes. Three independent lines of Lck-Bcl-2-Y28A mice (line Y28A-A, Y28A-C, and Y28A-E) expressed high levels of Bcl-2 comparable to Lck-Bcl-2-WT ( Figure 1a ). All the three Lck-Bcl-2-Y28A transgenic lines (A, E, C) protected thymocytes from apoptosis comparable to wild-type Bcl-2 (Figure 1b) , which is consistent with previous reports regarding the antiapoptotic function of this mutation (Huang et al., 1997) . The presence of the Y28A mutation in Bcl-2 was confirmed by sequencing the transgene amplified from genomic DNA (Figure 1c) . Figure 1 Expression and antiapoptotic function of Y28A mutant Bcl-2 transgenic lines. (a) Total cellular protein was prepared from freshly isolated thymocytes and purified splenic T cells from Bcl-2 Y28A lines A, E, C, Lck-Bcl-2 (WT), and transgene-negative control mice (Neg). Samples were separated on 12% SDS-PAGE gels and analysed for human Bcl-2 expression by Western blot (6C8). Blots were also probed with actin as a loading control. (b) Thymocytes from mice of the indicated genotype were cultured for 2 days prior to the detection of apoptosis by flow cytometry using Annexin V-FITC-propidium iodide (PI) staining. The percent of cells that are Annexin V and PI negative is plotted. The data represent mean7s.d. of triplicate samples. WT ¼ wild-type Bcl-2,
Chromatograph of Y28A sequence. Genomic DNA from a transgenic Y28A-C Bcl-2 mouse was amplified and sequenced as described in Materials and methods. The predicted protein sequence is indicated above the chromatograph. The expected 'TAC' from wild-type Bcl-2 is replaced with GCC encoding an alanine residue, confirming the introduction of the mutation in these transgenic mice Bcl-2 regulation of T-cell proliferation N Cheng et al Decreased splenic T cell proliferation in Lck-Bcl-2-Y28A mice Lck-Bcl-2-WT thymocytes were previously shown to have reduced proliferation (Linette et al., 1996) . Therefore, thymocytes from Lck-Bcl-2-Y28A mice were isolated and examined for proliferation based on cell cycle analysis with propidium iodide. As was found in Lck-Bcl-2-WT mice, thymocyte proliferation was dramatically reduced (data not shown). However, inhibition of thymocyte proliferation in vivo may be secondary to the lymphocytosis that develops in these mice. Therefore, to directly test the effect of Y28A Bcl-2 on the rate of cell cycle progression from quiescent cells, T cells from adult mice were purified, activated with anti-CD3 antibody, and cell proliferation was determined by propidium iodide staining of DNA content. Surprisingly, T cells expressing Y28A Bcl-2 consistently demonstrated decreased proliferation nearly identical to that seen in the Lck-Bcl-2-WT T cells (Figure 2a ). Similar results were found when proliferation was quantitated using 3 H thymidine uptake ( Figure 2b ).
Bcl-2 inhibition of T-cell proliferation is more pronounced with age
Previous studies found that the effects of Bcl-2 on proliferation in vitro were more pronounced in cells with prolonged quiescence (Marvel et al., 1994) . Consistent with this observation, we found that Bcl-2 only slightly inhibited T-cell proliferation when the cells were isolated from young mice (Figure 3a) . Interestingly, proliferation of nontransgenic T cells was also delayed in 10.3-weekold mice relative to 2.3-week-old mice. For all three transgenic lines, the ability of Bcl-2 to inhibit T-cell proliferation was compared between immature (o25 days) and mature (435 days) mice. Cell cycle inhibition was determined relative to an age-matched littermate control that was performed simultaneously. Significantly more inhibition was observed in T cells of mature mice than immature mice in all the three transgenic lines (Figure 3b ). One explanation for these results would be that Bcl-2 expression is not as high in T cells isolated from younger mice. However, the Lck proximal promoter used in these mice has been shown to express higher in thymocytes than mature T cells (Garvin et al., 1990) . More importantly, protein expression in mature splenic T cells was not affected by the age of the animal ( Figure 3c ). When placed in culture without activation, murine T cells demonstrate extensive cell death that is inhibited by Bcl-2 (Knudson and Korsmeyer, 1997) . When T cells from mice of various ages were examined for apoptosis, Bcl-2 demonstrated significant protection that was largely independent of age (data not shown).
The age-dependent effects of Bcl-2 can be further demonstrated by graphing the relationship between relative cell proliferation and animal age ( Figure 4 ). All the three transgenic lines (wild type, Y28A-A, and Y28A-C) showed a significant inverse relationship between animal age and cell cycle proliferation relative to the nontransgenic age-matched control. Using
Pearson's coefficient of correlation for all the three groups combined, the relationship between age (weeks) and relative cell cycle proliferation was highly significant (Po0.0001), with r ¼ À0.76 ( Figure 4 ). These results demonstrate that Bcl-2 antiproliferation effects on T cells are age dependent, and suggest that the ability of Bcl-2 to regulate cell proliferation is secondary to changes in the properties of the T cells that occur as the animal ages.
Inhibition of proliferation correlates with decreased cell size in T cells expressing wild type or Y28A Bcl-2
Recent studies suggest that quiescent T-cell survival is controlled by the expression of Bcl-2 family members as H-thymidine incorporation 48 h after activation, as described in Materials and methods. The mean7s.d. of four replicates is shown. Genotypes are as indicated in panel a. Significant differences were found between control and transgenic mice. P-values o0.001 in comparing control cells to those expressing mutant (Y28A) or wild-type Bcl-2 in both panels a and b (Student's t-test)
Bcl-2 regulation of T-cell proliferation N Cheng et al well as constitutive activation of NF-kB (Bureau et al., 2002) . We examined whether Bcl-2 expression results in changes in cell size as an indicator of quiescence. As previously reported (Linette et al., 1996) , T cells from adult Bcl-2 transgenic mice demonstrated decreased cell size, as measured by flow cytometry (Figure 5a ). In contrast, the size of T cells from immature mice expressing Bcl-2 was not significantly different from controls ( Figure 5b ). Comparison of freshly isolated T cells from Y28A-C mice of different ages shows that Tcell size, measured by forward scatter, is decreased with increasing age (Figure 5c ). These data demonstrate that Bcl-2 changes in cell size are age dependent, paralleling the age-dependent effects on proliferation. Furthermore, all three transgenic lines (wild type, Y28A-A and Y28A-C) showed a significant relationship between T-cell size and cell cycle proliferation relative to the nontransgenic age-matched control. Using Pearson's coefficient of correlation for all the three groups combined, the relationship between the relative cell size (mean forward scatter (FSC) of Bcl-2 transgenic T cells divided by mean FSC of T cells from transgene-negative controls) and relative cell proliferation was highly significant (Po0.0001), with r ¼ 0.71 ( Figure 6 ).
Bcl-2 expression is associated with decreased Pyronin Y staining
Distinction between G0 and G1 phases of the cell cycle can be difficult. However, quiescent cells in G0 contain less total RNA. Therefore, Pyronin Y staining of RNA in combination with DNA staining with Hoescht can distinguish quiescent G0 from G1 cells . As predicted from the cell size data, T cells expressing either wild-type or Y28A mutant Bcl-2 showed deceased Pyronin Y staining (Figure 7 ). Pyronin Y fluorescence increases as cells transit from G0 to G1, and young (o25 days) mice of the indicated genotype were activated with CD3 and proliferation determined with PI staining. Cell cycle inhibition was determined by comparison with agematched control littermate. The mean and s.d. of at least three mice/group is shown. The asterisk (*) indicates that the 435-dayold group was significantly different (Po0.001) than the o25-dayold group of the same genotype (Student's t-test). Differences between WT and Y28A-A, C mice were not statistically significant. The average ages of the young mice were as follows: WT Bcl-2 mice (20.3 days, n ¼ 3), Y28A-A (15.3 days, n ¼ 3), and Y28A-C (14 days, n ¼ 6). (c) T cells from Lck-Bcl-2 ( þ ) and Ctrl (À) mice of the indicated ages were extracted with Triton X-100 extraction buffer and separated on 12% SDS-PAGE. The immunoblots were probed with Hamster anti-human Bcl-2 (6C8), followed by anti b-actin as a loading control. Quantification of Bcl-2 normalized with actin using NIH Image found no decrease in Bcl-2 expression in young animals (data not shown) Figure 4 Age-dependent inhibition of cell proliferation by both wild-type and Y28A mutant Bcl-2. Compilation of multiple experiments performed on Lck-Bcl2 WT, Y28A-A, and Y28A-C T cells is shown. T cells were purified and activated with immobilized anti-CD3 for 41-49 h prior to determining the percent of S, G2 or M by propidium iodide staining for DNA content. In each case, the percent of cells in the S þ G2 þ M phase of the cell cycle was determined and normalized to the nontransgenic littermate control to determine the relative proliferation (divide Bcl-2 regulation of T-cell proliferation N Cheng et al reflecting RNA synthesis. Early after activation (22 h), T cells from mice that were 2.3-weeks old, pyronin Y staining of both control and Bcl-2 cells increased dramatically, indicating that transition into G1 has occurred in both lines (Figure 8a , left panel). In T cells from 5-week-old mice, the proportion of cells with low Pyronin Y staining was increased by Bcl-2 compared to control cells. This indicates that G0-G1 transition has occurred in nearly all the control but only a portion of the Bcl-2 cells (Figure 8a , middle panel). Interestingly, by 8 weeks of age, the proportion of cells with low pyronin Y staining was increased in both control and Bcl-2 T cells, but the proportion is higher in the Bcl-2 line ( Figure 8a , right panel). These results indicate that Bcl-2 expression results in prolonged G0 relative to controls in both 5-and 8-week-old mice. Consistent with age-dependent inhibition of proliferation (Figures 3, 4) , overlays of pyronin Y peaks of activated T cells from mice of increasing ages demonstrate that the rate of entry into G1 is inversely related to age, but Bcl-2 exerts an additional inhibitory effect beginning at age 5 weeks (Figure 8b ).
p27 levels are associated with cell cycle inhibition by Bcl-2
Previous studies demonstrate that Bcl-2 results in elevated p27 levels and that p27 is required for the effects of Bcl-2 on T-cell proliferation (Linette et al., 1996; Vairo et al., 2000; Greider et al., 2002) . Therefore, p27 levels were examined in quiescent T cells from Bcl-2 and control mice of varying ages. As previously described for wild-type Bcl-2 (Linette et al., 1995) , p27 levels were elevated in T cells from mature Y28A-C mice, which also exhibited delayed activation (Figure 9 ). Consistent with large cell size and higher RNA content ( Figures 5, 7) , p27 level was lower in T cells of young mice, signifying less effective G0 arrest. Interestingly, Bcl-2 did not significantly affect p27 levels in T cells from young mice, which also were not delayed by Bcl-2 during activation ( Figure 9 ). This result shows that the antiproliferative activity of Bcl-2 corresponds to high resting p27 levels, and thus the degree of cell cycle arrest. The changes in cell size, RNA content, and p27 expression provide molecular evidence that cell Figure 6 Modulation of cell proliferation by Bcl-2 correlates with cell size. Purified T cells from wild-type Bcl-2 (WT), and Lck-Bcl-2 Y28A (Y28A-A and Y28A-C) and transgenic-negative littermates, were activated by anti-CD3 antibody for 41-49 h. Relative proliferation was determined as described in Figure 4 . The initial (time 0) relative cell size of the CD3-positive cells was determined by flow cytometry (mean-forward scatter). For each data point, the transgene-positive sample was normalized to the value for transgene-negative age-matched (generally littermate) control. The data in aggregate were analysed using Pearson's coefficient of correlation. Results from statistical analysis are as follows for all the three groups together:
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Bax antagonizes the antiproliferative activity of Bcl-2
Bax and Bcl-2 have opposite apoptotic functions (Oltvai et al., 1993) . To determine if Bax can antagonize the antiproliferative function of Bcl-2, mice expressing both Bax and Bcl-2 were generated, and the proliferation of T cells was determined. Consistent with inhibition of cell survival in vivo, T cells from mice expressing both Bax and Bcl-2 were larger than those expressing Bcl-2 alone (Figure 10a ). Furthermore, Bax antagonized the antiproliferative activity of Bcl-2, as measured by either 3 Hthymidine (Figure 10b ) or propidium iodide staining (Figure 10c ). Bax did not increase cell proliferation, as the amount of cell death offsets any acceleration in cell cycle entry (Knudson et al., 2001) . The data demonstrate that Bax antagonizes both the antiapoptosis and antiproliferative effects of Bcl-2. Our interpretation is that Bax expression prevents prolonged survival of Bcl-2-expressing T cells and therefore the delay in proliferation.
Discussion
We demonstrate for the first time that the inhibition of T-cell activation by Bcl-2 is age-dependent. We found that the kinetics of T-cell activation decrease with age and directly correlate with age-dependent decreases in T-cell size, RNA content, and increases in p27 levels. Our data indicate that with increasing age, T cells progressively arrest further into G0 and require more time to re-enter the cell cycle following activation. Bcl-2 enhances this age-dependent decrease in cell proliferation.
The regulation of cell proliferation by Bcl-2 in cell culture and animal models has been described extensively. The antiproliferative activity has been proposed to account for the antioncogenic activity of Bcl-2 that has been observed in some models (Pietenpol et al., 1994; de la Coste et al., 1999; Murphy et al., 1999) . To date, these have all been correlative studies, and proof that the antioncogenic activity of Bcl-2 is mediated by its antiproliferative function is lacking. Recent studies suggested that the antiapoptotic and antiproliferative activities of Bcl-2 were separated by the introduction of mutations into Bcl-2 (Uhlmann et al., 1996; Huang et al., 1997) . Specifically, mutation of Tyrosine 28 in the BH4 domain inhibited the antiproliferative activity of Bcl-2, without affecting the antiapoptotic function (Huang et al., 1997) . This was observed for three different mutations of tyrosine 28, and was observed in multiple cell types (Vairo et al., 2000) .
Separation of the antiproliferative and antiapoptotic functions of Bcl-2 would have important clinical implications. For example, inhibition of the antiapoptotic function of Bcl-2 without disruption of the antiproliferative activity may be an important therapeutic goal. Conversely, loss of the antiproliferative function of Bcl-2 without loss of antiapoptotic activity may enhance predisposition to tumor formation. In the studies described herein, Bcl-2 expressing the tyrosine 28-to-alanine mutation was introduced into transgenic mice; so we could examine the function of this molecule in vivo. To our surprise, the Y28A mutant Bcl-2 was still able to inhibit T-cell proliferation to the same extent as wild-type Bcl-2.
Several possibilities may explain the discrepancy between our results and those of Huang et al. (1997) . First, the results may differ due to differences between immortalized cell lines and primary cells. Previous results were done in cell lines such as FDP-P1, NIH 3T3 fibroblasts, and BRK cells, while our results were in primary murine cells. We do not favor this hypothesis as we have found that Bcl-2-Y28A is able to inhibit cell proliferation in NIH-3T3 fibroblasts . Alternatively, cell type may be a contributory factor as the studies described here are limited to T lymphocytes in which cell proliferation may be uniquely regulated. However, for the same reason mentioned Bcl-2 regulation of T-cell proliferation N Cheng et al above, we do not favor this alternative. A third possibility is that the apparent differences between wild-type and Y28 mutant Bcl-2 may be due to distinct clonal changes that are independent of Bcl-2 expression. This possibility is very unlikely in the transgenic mice described here, as mice from three independently derived transgenic lines were analysed. Whether cell differences or clonal differences account for this discrepancy, our results clearly demonstrate that Y28A Bcl-2 retains antiproliferative function in T lymphocytes.
Other studies have found links between apoptosis and proliferation that appear to be dependent on specific signaling pathways. For example, T-cell proliferation is positively regulated by the FAS pathway. Inhibition of the FAS pathway by disruption of FADD (Newton et al., 1998) or treatment with caspase inhibitors also inhibits T cell proliferation (Kennedy et al., 1999) . As Bcl-2 is known to block caspase activation in most apoptotic pathways, it is possible that this accounts for the antiproliferative activity of Bcl-2.
Overexpression of Bcl-x L or Bcl-2 in T cells decreases T-cell size, ATP levels, and results in delayed T-cell proliferation (Linette et al., 1996; Rathmell et al., 2000) . Our results extend these findings and demonstrate that the antiproliferative activity of Bcl-2 increases with age and this activity is minimal in immature mice. The expression levels of Bcl-2 do not appear to account for these age-dependent differences. As Bcl-2 leads to lymphocytosis (between birth and B3 weeks), we propose, trophic support becomes rate limiting, cell metabolism is decreased, cells become smaller, RNA levels are decreased, and p27 is increased. In vivo, T-cell survival appears to depend on the interaction and recognition of MHC (Rathmell et al., 2000) . The ability of Bcl-x L to inhibit cell proliferation was found to correlate with decreased cell size and metabolism (Rathmell et al., 2000) . In the Bcl-2 transgenic mice described here, lymphocytosis may result in decreased interactions between T cells and MHC, effectively reducing trophic support and resulting in decreased metabolism and cell size. Consistent with this interpretation, Bcl-2-expressing T cells become larger when passively transferred to T cell-deficient, Rag1À/À mice (Rathmell et al., 2000) . For T cells, our data suggest that the effects on cell cycle are secondary to prolonged Tcell survival. This interpretation is further supported by recent results that show that Bcl-2-expressing and control fibroblasts sorted to maintain a similar cell size Figure 9 Age-dependent effects of Bcl-2 on p27 levels. p27, actin, and human BCL-2 were detected by immunoblotting, as described in Materials and methods. Levels from splenic T cells of control (À) and Y28A Bcl-2 ( þ ) transgenic mice (Y28A-C) at the indicated age (weeks) are shown. Results are representative of several independent experiments
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These results favor a model that the antiapoptotic and antiproliferative functions of Bcl-2 are not genetically separate and most likely result from a common function.
Materials and methods
Transgenic mice
The Y28A mutation was introduced into Bcl-2 by overlap extension PCR (Horton et al., 1993) , essentially as previously described (Huang et al., 1997) . The Lck pr -Bcl-2 Y28A construct was generated by ligation of the Y28A mutant Bcl-2 into the BamHI site of the Lck pr -hGH vector (Sentman et al., 1991) . This promoter has been used previously for high expression of wild-type Bcl-2 in T cells (Sentman et al., 1991) . The final plasmid (Plasmid 33 ¼ Lck-Bcl-2-Y28A) was completely sequenced to confirm the presence of the Y28A mutation and the absence of any additional mutations introduced by PCR. The construct was then used to generate transgenic mice using the Transgenic Animal Facility at the University of Iowa. Briefly, pronuclei from fertilized oocytes (C57BL/SJL F1 crosses) were injected with linearized DNA and the oocytes were incubated overnight prior to transplantation into the oviduct of pseudopregnant mice. Eight independent lines were generated, of which five were able to successfully propagate the transgene. Three of these five lines expressed high levels of protein and were chosen for subsequent analysis. Mice were subsequently backcrossed and maintained on the C57BL/6 background. No changes in phenotype have been observed with continued backcross to C57BL/6. The animals were genotyped as previously described for Lck-Bcl-2 (Knudson and Korsmeyer, 1997) . Given the discrepancy between our results and previous results in cell lines, the Y28A mutation was confirmed in LckBcl-2 Y28A line C by PCR amplification of the transgene and sequencing of the PCR product. Briefly, the transgene was amplified from genomic DNA using a forward primer from the Lck Promoter (5 0 -CCC AGT CAG GAG CTT GAA TC-3 0 ) and reverse primer from Bcl-2 downstream from the mutation (5 0 -AGG GTC AGG TGG ACC ACA G-3 0 ). The PCR product was then sequenced with the Lck promoter primer.
For comparison, the Lck pr -Bcl-2 wild-type transgenic mice were obtained from Jackson laboratory (#002427). Both the wild-type and Y28A mutant Bcl-2 transgenic animals were genotyped using transgene-specific primers (hGH and Bcl-2), as previously described (Knudson and Korsmeyer, 1997) . To distinguish the mice expressing Y28A mutant Bcl-2 from those expressing wild-type Bcl-2, the following nomenclature will be used: mice expressing wild-type Bcl-2 will be denoted Lck-Bcl-2-WT or WT, while those generated from plasmid 33 and expressing the Y28A mutant Bcl-2 will be denoted Lck-Bcl-2-Y28A, and lines A, C or E will be named Y28A-A, Y28A-C, and Y28A-E, respectively. For some experiments, Lck-Bax transgenic mice (lines 1 and 38) were crossed to Lck-Bcl-2 WT and Y28A-C lines. These lines were genotyped as previously described (Knudson et al., 2001) . In some experiments, mice positive for both Lck-Bax lines 1 and 38 (Bax38&1) were used as previously described (Luke et al., 2003) .
Cell preparation and activation
Single-cell suspensions from either the spleen or thymus were prepared by dispersing the organ between two glass slides in PBS. When necessary, red blood cells were removed by a 5-min incubation in hypotonic lysis buffer (0.83% NH 4 Cl, 10 mM Tris/pH 7.2). The viable cell counts were determined using a hemocytometer and trypan blue exclusion (Linette et al., 1996) . Splenic T cells were prepared by two methods. In some experiments, T cells were prepared by negative selection using anti-B220, HSA, and Mac-1 antibodies, as previously described (Knudson and Korsmeyer, 1997) . Alternatively, T cells were purified using reagents and protocols from Stem Cell Technologies (product #13051). No differences were observed between the two methods. Purified T cells (200 000 cells/well) were seeded onto 96-well plates that were precoated with saturating amounts of anti-CD3 antibody (145-2C11 eBioscience #16-0031-85), as previously described (Knudson and Korsmeyer, 1997) . At various times following activation, cells were harvested and prepared for cell cycle analysis. T-cell purity was determined by CD3 staining (FITC-anti-CD3 Pharmingen #553062) and analysed using flow cytometry, as previously described (Knudson and Korsmeyer, 1997) . Cells were cultured in RPMI-1640 supplemented with 10% FBS, 0.1 mM 2-mercaptoethanol, 200 mM glutamine, and penicillin/ streptomycin.
Cell analysis of viability, proliferation and size
Cell viability was determined using double staining with Annexin V-FITC (Santa Cruz Biotechnology) and propidium iodide, as instructed by the manufacturer. Samples were analysed using a FACSCalibur from Becton Dickenson. Cell cycle analysis was performed by analysing propidium iodidestained nuclei on a flow cytometer equipped for doublet discrimination (FACScan or FACSCalibur from Becton Dickinson). Briefly, B1 million cells were centrifuged and suspended in 0.5 ml of Krishan reagent (0.1% Na citrate, 0.03% NP-40, 0.05 mg/ml PI, 0.02 mg/ml RNase A) prior to analysis, as previously described (Knudson et al., 2001) . The percent of cycling cells (%S þ G2 þ M) was determined by examining histograms after gating out doublet events based on FL-2 area vs FL-2 width. Subdiploid cells (o2 N) were included in the analysis (except where indicated in the legend) to be sure that Bcl-2 effects on cell death could not explain the decreased proliferation. Nonetheless, in our experiments with CD3-activated T cells, cell death in control and Bcl-2 transgenic mice were similar (data not shown). Therefore, decreased cell death in the Bcl-2 transgenic mice will not influence the amount of proliferation. Cellquest software (Becton Dickinson) was used for both the acquisition and analysis of all flow cytometry data. Alternatively, cells were activated for 24 h, followed by the addition of 1 mCi 3 H thymidine per well for an additional 24 h.
3
H thymidine uptake was determined using an Inotech cell harvester, following the manufacturer's instructions. The counts of 3 H thymidine were read with a scintillation counter. The CPM value represents the mean of quadruplicate samples and was normalized by the number of CD3-positive T cells in each well.
For cell size analysis, splenic T cells were stained with CD3-FITC and forward scatter was then analysed on the CD3-positive population. In all cases, samples from Bcl-2-positive mice were prepared and analysed simultaneously with agematched littermate controls. To minimize the experimental variation, data from multiple experiments were plotted following normalization of the data from the transgenic mouse relative to the data from the age-matched control animal. As an example, if the initial mean forward scatter for the Lck-Bcl-2 transgenic is 390 and the control is 430, the value for the Bcl-2 animal is 390/430 ¼ 0.91.
Statistical analysis
Groups were compared using the Student's t-test (nonpaired), assuming unequal variances. Correlation analysis was performed using Pearson's coefficient of correlation using the Statistica analysis software.
Protein analysis
Cells were lysed in RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 100 mg/ml PMSF, protease inhibitor cocktail (Boehringer Mannheimin), and 1 mM sodium orthovanadate in 1 Â PBS) or Triton buffer (1% Triton, 150 mM NaCl, and 50 mM Tris-Hcl 8.0, 100 mg/ml PMSF, protease inhibitor cocktail) at 10 ml/million cells for 30-60 min on ice. Equal amounts of protein (Bradford assay-Bio-Rad Cat#500-0006) were loaded on 12% SDS-PAGE (Novex mini gels), transferred to nitrocellulose membrane, and immunoblotted with anti-Bcl-2 (6C8 -available from Pharminigen) or anti-p27 (Transduction Labs, Cat# 610242). Primary antibodies were detected with appropriate HRP-conjugated secondary antibodies followed by chemiluminescent detection (NEN), as previously described (Knudson and Korsmeyer, 1997) . For normalization of loading, blots were stripped at 501C for 30-60 min in buffer (2% SDS, 100 mM 2-mercaptoethanol, 62.5 mM Tris-HCl (pH 6.8)), washed with PBSTween (0.05%) six times and probed for b-actin (Sigma Cat #A 4700).
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